Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study

• Main Authors: Helison R. P. Carmo (Author), Alejandro Rossel Castillo (Author), Isabella Bonilha (Author), Erica I. L. Gomes (Author), Joaquim Barreto (Author), Filipe A. Moura (Author), Gustavo Gastão Davanzo (Author), Lauar de Brito Monteiro (Author), Stéfanie Primon Muraro (Author), Gabriela Fabiano de Souza (Author), Joseane Morari (Author), Flávia Elisa Galdino (Author), Natália S. Brunetti (Author), Guilherme Reis- (Author), Victor Corasolla Carregari (Author), Wilson Nadruz (Author), Daniel Martins- (Author), Alessandro S. Farias (Author), Licio A. Velloso (Author), José Luiz Proenca-Modena (Author), Marcelo A. Mori (Author), Watson Loh (Author), Deepak L. Bhatt (Author), Derek M. Yellon (Author), Sean M. Davidson (Author), Pedro G. De Oliveira (Author), Pedro M. Moraes-Vieira (Author), Andrei C. Sposito (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is linked to high mortality, primarily through an intense inflammatory response. Diacerein has emerged as a potential therapy for COVID-19 due to its potential impact in decreasing the inflammasome activation and coronavirus repl...